PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
- 1 July 2008
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 5 (3) , 481-489
- https://doi.org/10.1016/j.nurt.2008.05.003
Abstract
No abstract availableKeywords
This publication has 122 references indexed in Scilit:
- Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neuronsProceedings of the National Academy of Sciences, 2008
- Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer diseaseJournal of Clinical Investigation, 2008
- PPARs in the brainBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptorsProceedings of the National Academy of Sciences, 2007
- Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease)The Pharmacogenomics Journal, 2006
- Going nuclear in metabolic and cardiovascular diseaseJournal of Clinical Investigation, 2006
- PioglitazoneDrugs, 2006
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- Divergent Effects of Peroxisome Proliferator-activated Receptor γ Agonists and Tumor Necrosis Factor α on Adipocyte ApoE ExpressionJournal of Biological Chemistry, 2004
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003